Contineum Therapeutics(CTNM)

Focus: Contineum Therapeutics is a publicly traded biotech focused on small-molecule therapeutics for multiple sclerosis and respiratory diseases, headquartered in San Diego. The company is in early-stage clinical development with a lean operational footprint.

Neurology Respiratory

Profile data last refreshed 9h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

Should You Work at Contineum Therapeutics?

AI assessment

Contineum is a high-risk, early-stage play suitable only for scientists comfortable with pre-commercial biotech volatility and willing to bet on pipeline potential rather than near-term stability.

Why Work Here

Public company status provides liquidity and potential equity upside with analyst buy ratings from Stifel Nicolaus and JonesTrading as of September-October 2026.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$50M

Pipeline & Clinical Trials

PIPE-307

Multiple Sclerosis

PHASE_1

Clinical Trials (1)

NCT04725175Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers

Phase 1

Help build intelligence for Contineum Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-need areas (MS, IPF, hearing loss, pain) with multiple programs in Phase 1-2 allowing career specialization in neurology and respiratory therapeutics.

San Diego location offers access to major biotech cluster and network effects for pharma talent mobility.

Watch Out For

Company swung to $42.3M net loss in FY 2025 despite only $38M R&D spend, signaling cash burn and limited runway with just $22M cash on hand.
Minimal hiring activity (1 active role in Facilities) combined with declining headcount trajectory suggests limited career growth and advancement opportunities.
No Phase 3 programs and no approved products means 5+ years minimum to potential first market success, exposing early-stage risk.

Generated by Claude from Contineum Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

PIPE-791

Chronic Osteoarthritis Pain

PHASE_1

Clinical Trials (1)

NCT06810245Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

Phase 1

PIPE-791

Multiple Sclerosis

PHASE_1

Clinical Trials (1)

NCT05983939Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers

Phase 1

PIPE-791

Idiopathic Pulmonary Fibrosis (IPF)

PHASE_1

Clinical Trials (1)

NCT06683612PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF

Phase 1

PIPE-307

Multiple Sclerosis

PHASE_1

Clinical Trials (1)

NCT04941781PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers

Phase 1

PIPE-505

Sensorineural Hearing Loss

PHASE_1_2

Clinical Trials (1)

NCT04462198Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss

Phase 1/2

PIPE-791 Dose A

Idiopathic Pulmonary Fibrosis

PHASE_2

Clinical Trials (1)

NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

Phase 2

Interview Prep Quick Facts

Portfolio: 7 clinical trials

Top TAs: Neurology, Respiratory

Publications: 9 in PubMed

SEC Filings: 2 available

Open Roles: 1 active job

Therapeutic Area Focus

Neurology

4 pipeline

Respiratory

2 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$38M39%

Net Income

-$42M

Cash

$22M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(9)

Recent peer-reviewed publications with author affiliations at this company

Discovery of PIPE-791, A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders.

Journal of medicinal chemistry

2026

PMID:42370792

Additives Promote Divergent Reactivity in Photolytic Deoxygenation and Lactonization Reactions of Cobalt Alkoxycarbonyls.

European journal of organic chemistry

2026

PMID:42100026